CATEGORIES: CMT Update

BioPontis Aliance for Rare Disease: Joint Venture with HNF

by | Dec 9, 2014 | 1 comment

Bio Pontis HNF logo 2 (2)Hereditary Neuropathy Foundation (HNF) is pleased to announce the creation of a joint venture to develop drug candidates for the treatment of Charcot-MarieTooth (CMT) Disease with BioPontis Alliance for Rare Disease.  HNF has supported basic research into the cause of CMT and early translational research to develop critical tools for drug development, with the goal that research would lead quickly to treatment. Progress can become stalled because drug development requires a complex array of more engineering like technical capabilities, capabilities not available to patients and academic researchers alike. Also new attention must be paid to patenting and aligning to the interest/requirements of the drug industry players who will be needed to bring treatments to patients.

To ensure success of potential candidates that are ready to enter clinical trials—not at the earlier stage where potential treatments are first being developed and tested in cells or animal models multiple steps need to be taken—BioPontis Rare Disease Alliance can provide the scientific, business and patenting structure to help bridge to those pharmaceutical companies.

In the Joint Venture, BioPontis Alliance will manage the project’s scientific execution, regulatory strategy, patenting and business partnering. HNF will continue to manage the other important factors that support the drug discovery process, such as basic and early translational research, build and maintain the Global Registry for Inherited Neuropathies and conduct market research and clinical outcome measure research.

Learn more on this topic

Related Blog Posts

Double Your Donation

Corporate matching gift programs are charitable giving programs setup by corporations in which the company matches donations made by employees to eligible nonprofit organizations. For example, if a donor works for Bank of America and donates $100 to the Hereditary Neuropathy Foundation, Bank of America will double the donation by also writing a check for $100.

Taking Matters Into Your Own Hands

Do you have a rare form of CMT?

We were contacted recently from a patient with CMT2D who was looking for advice on how to make a difference. Our recommendations for all people with an ultra-rare form of CMT who want to get involved:

Now GRIN is Accessible in 141 Different Languages!

Now GRIN is Accessible in 141 Different Languages!

The Global Registry for Inherited Neuropathies (GRIN) has implemented Google Translate. Why did we choose Google? Because Google is leading the way in teaching computers how to interpret meaning, avoiding the traditional method of decoding language.

Accelerating Patient Access to Investigational Drugs in 2015

Accelerating Patient Access to Investigational Drugs in 2015

Currently the FDA is working to update the process for physicians applying for accelerated patient access to investigational drugs, while the drug or biological product is being tested in clinical trials. This will also be important for the CMT community as clinical trials for this disease are being launched.

Do You Have Charcot-Marie-Tooth Type 4 (CMT4)? – We Need Your Help

Autosomal recessive demyelinating CMT4 patients present with earlyonset and slowly progressing symptoms. These include progressive distally accentuated weakness and atrophy of muscles in the lower limbs. In addition, patients may have weakness and atrophy of hands, sensory loss and pes cavus (high-arched feet), and walking difficulties. Further information on CMT4 can be found at Orphanet.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Join the conversation

Leave a Comment

1 Comment

  1. Sue Windham

    I have a brother that has been going through this problem for at least 6/7 years. About 2 years ago a Neurologist found out they were treating him for everything but the right thing. She did many test but knew right off he had CMT. He has all the symptoms of the CMT. Started off with his feet and legs. No balance. Could barely walk. Then it hit his arms, hands and muscles. Now he is in a wheelchair. No one knows really what kind of medicine to give him but something to help the pain and anxiety. He has been trying to find a place where they would do a study on him. He is in really bad shape. If you could help me with this please e-mail me and let me know. He cannot use a computer so I am trying to find someone that will send him newsletters about the CMT so he can read it and get more history. I am afraid he is going to end up in a nursing home.

    Thank you so much for the consideration.

    Sue Windham

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news